EPO published patent application EP3471740A1 for the University of Utah Research Foundation covering compositions and methods for albumin-based nanomedicines. The patent focuses on therapeutic applications including cancer treatment (A61P35/00), with IPC classifications in drug carriers (A61K47/64, A61K47/68) and antisense oligonucleotides (A61K31/712). Inventors are Kopeck and Yang. The designated states cover all major European Economic Area countries.

This patent publication does not impose compliance obligations on third parties. Organizations developing albumin-based drug delivery systems should review the patent claims to assess freedom-to-operate. Companies seeking to commercialize similar nanomedicine technologies may need to evaluate licensing opportunities or design-around strategies. The patent provides IP protection for the applicants without creating regulatory requirements for other market participants.